FAT1 and non-small cell lung carcinoma: For example, Feng et al. curated comprehensive somatic mutational profiles and clinical immunotherapy information from NSCLC patients and found that FAT1 mutations were predictive of favorable tumor immune infiltration and, importantly, better ICI treatment efficacy [4].